ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGTC Applied Genetic Technologies Corporation

0.3936
0.00 (0.00%)
Apr 22 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.4329
Ask Price 0.3739
News -
Share Name Share Symbol Market Stock Type
Applied Genetic Technologies Corporation AGTC NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.3936 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.3936 0.3936
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0 US$ 0.3936 USD

Applied Genetic Technologies Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 26.62M - - - -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Applied Genetic Technolo... News

Real-Time news about Applied Genetic Technologies Corporation (NASDAQ): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AGTC Message Board. Create One! See More Posts on AGTC Message Board See More Message Board Posts

Historical AGTC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Applied Genetic Technolo... Description

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.

Your Recent History

Delayed Upgrade Clock